

MARKERS FOR PROSTATE CANCER

Abstract of the Disclosure

5 This invention provides a method for determining the
aggressiveness of a prostate carcinoma comprising: (a)
obtaining a sample of the prostate carcinoma; and (b)
detecting the presence of p27 protein in the prostate
carcinoma, the absence of p27 indicating that the prostate
10 carcinoma is aggressive. This invention also provides a
method for diagnosing a benign prostate hyperplasia
comprising: (a) obtaining an appropriate sample of the
hyperplasia; and (b) detecting the presence of the p27 RNA,
a decrease of the p27 RNA indicating that the hyperplasia
15 is benign. This invention provides various uses of p27 in
prostate cancer. Finally, this invention also provides
different marker for prostate cancer.